Pure Bioscience Inc Stock Price, News & Analysis

PURE Bioscience (OTCQB: PURE) has signed a multi-year distribution agreement with Bonsai, a premium American-made cleaning solutions provider, to expand market access for its patented silver dihydrogen citrate (SDC) antimicrobial products. The partnership enables direct-to-customer sales through Bonsai's online platform.

PURE's flagship product, PURE Hard Surface, is an EPA-registered disinfectant featuring the lowest EPA toxicity rating, no rinse requirement on food contact surfaces, and 99.999% kill times in 30 seconds. The SDC technology works through a dual-action mechanism, deactivating membrane proteins and denaturing DNA of microorganisms.

PURE Bioscience (OTCQB: PURE) reported fiscal Q3 2025 results with net product sales of $489,000, up from $440,000 in Q3 2024. Despite the quarterly sales growth, the company posted a net loss of $580,000, improved from $857,000 loss in Q3 2024. For the nine-month period, sales declined to $1.435M from $1.483M year-over-year, while net loss improved to $2.067M from $2.594M. The company highlighted progress in its dairy membrane solution using SDC technology, demonstrating effectiveness in commercial dairy plants. PURE continues focusing on developing antimicrobial products for the food and beverage industry, with its patented silver dihydrogen citrate (SDC) technology offering superior efficacy and reduced toxicity compared to existing solutions.

PURE Bioscience (OTCQB: PURE) has introduced a revolutionary membrane treatment solution for the dairy and beverage industry using PURE® Hard Surface, powered by their patented silver dihydrogen citrate (SDC) antimicrobial technology. The solution effectively addresses membrane fouling and sanitization challenges, achieving a 4+ log reduction in 120 seconds. Key features include complete membrane penetration within 5 minutes for RO systems, immediate penetration for UF systems, no requirement for PPE due to low EPA toxicity rating, and environmental safety. The ready-to-use formula requires no mixing and helps manufacturers reduce operational costs while extending membrane lifespan. The SDC technology works through a dual-action mechanism, deactivating membrane proteins and denaturing DNA of microorganisms, with a shelf life of several years.

PURE Bioscience (OTCQB: PURE) reported its fiscal Q2 2025 financial results, showing mixed performance. Net product sales increased to $391,000 in Q2 2025 from $325,000 in Q2 2024, driven by expanded distribution network sales. The company reduced its quarterly net loss to $798,000 from $1,002,000 year-over-year.

For the six-month period, net product sales decreased to $946,000 from $1,043,000, while net loss improved to $1,487,000 from $1,737,000. The company achieved significant cost reductions through decreased personnel costs, professional fees, and share-based compensation.

A major milestone was advancing their dairy membrane solutions from laboratory testing to pilot scale at a California State University and commercial in-plant pilots. The company's non-oxidizing membrane solution for dairy operations demonstrates benefits in water conservation, energy efficiency, fouling removal, and operational cost reduction through minimized Clean-In-Place cycle downtime.

PURE Bioscience (OTCQB: PURE) has signed a multi-year distribution agreement with Hydrite Chemical Company for the purchase and selling of SDC (silver dihydrogen citrate) products. The partnership builds upon an eight-year relationship between the companies and aims to expand the reach of PURE's antimicrobial technology through Hydrite's established distribution network.

The SDC technology works through a dual-action mechanism: silver ions deactivate structural and metabolic membrane proteins while also entering microbes as a perceived food source to denature DNA, preventing replication. Unlike traditional silver-based disinfectants with short shelf lives, SDC remains stable for several years. The agreement positions PURE to strengthen its market presence while enhancing Hydrite's product portfolio in food processing and other markets.

PURE Bioscience (OTCQB: PURE), developer of patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, has launched a comprehensive rebranding campaign in collaboration with Greenville (bbG). The initiative aims to reinforce the company's market presence and reflect its dedication to advancing antimicrobial and disinfection solutions for the food and beverage industry.

The new brand identity features a minimalist logo combining a wordmark with a molecular-inspired icon, representing the SDC molecule through three interconnected circles that also form a 'p' shape. The rebranding effort, led by bbG, includes a cohesive visual identity and messaging framework aligned with PURE's long-term objectives and commitment to innovation in cleaning and disinfection solutions.

PURE Bioscience (OTCQB: PURE) reported financial results for fiscal Q1 2025 ended October 31, 2024. Net product sales decreased to $555,000 from $718,000 in the same quarter last year, primarily due to budgetary constraints of a major customer. The company's net loss improved slightly to $689,000 compared to $735,000 in Q1 2024. Net loss per share remained stable at ($0.01).

CEO Robert Bartlett noted that while the company continues to develop its business strategy with key distributors, the process is taking longer than expected. PURE is investing resources in onboarding new distributors, training, and marketing initiatives to expand their product offerings across the food and beverage industry.

PURE Bioscience (OTCQB: PURE) has signed a multi-year distribution agreement with AFCO, a Zep Company, for their patented SDC (silver dihydrogen citrate) antimicrobial products. The strategic partnership aims to leverage AFCO's extensive network in the food and beverage sector. SDC technology offers a dual-action antimicrobial solution with a unique shelf life of several years, unlike traditional silver-based disinfectants that last only hours to days. The collaboration focuses on expanding product applications and providing innovative solutions throughout North America.

PURE Bioscience (OTCQB: PURE) has signed a multi-year distribution agreement with Quip Laboratories for its patented SDC (silver dihydrogen citrate) antimicrobial products. The partnership aims to enhance product accessibility across biomedical research, pharmaceutical production, companion animal care, and food processing industries. SDC's dual-action antimicrobial technology works by deactivating membrane proteins and denaturing DNA in microbes, offering a stable shelf life of several years compared to traditional silver-based disinfectants.